← Back to headlines
AstraZeneca Stock Plunges After Heart Disease Drug Fails Trial
AstraZeneca's shares experienced a significant drop following the failure of a new heart disease drug in its clinical trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.